| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70532
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70539
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001102 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate |
2002-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f50209b83948dbdd183d6b736dfa2ddb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b613a6eb569a2f844fa3a1783298313c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9d7474ad5cce20fa52554279d02483d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9151134af3a67a00e84432615ba14063
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17e294cdec93ba37a65aaaa8903a4294 |
| publicationDate |
2003-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2003124103-A1 |
| titleOfInvention |
Tumor cells with increased immunogenicity and uses therefor |
| abstract |
Tumor cells modified to express a T cell costimulatory molecule are disclosed. In one embodiment, the costimulatory molecule is a CD28/CTLA4 ligand, preferably a B lymphocyte antigen B7. The tumor cells of the invention can be modified by transfection with nucleic acid encoding a T cell costimulatory molecule, by using an agent which induces or increases expression of a T cell costimulatory molecule on the tumor cell surface or by coupling a T cell costimulatory molecule to the tumor cell surface. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor. A method for specifically inducing a CD4+ T cell response against a tumor and a method for treating a tumor by modification of tumor cells in vivo are disclosed. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005276822-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7807186-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011165187-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7674456-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8444965-B2 |
| priorityDate |
1993-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |